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Abstract
Background: Primary care is likely to see the highest number of Lyme disease patients. Despite this, there is limited
published data regarding Lyme disease patients accessing primary care in the UK. We aim to describe trends in the
incidence of a new diagnosis, and demographics of patients identified in a primary care electronic health database.
Methods: A descriptive epidemiological study of Lyme disease coded patients in UK primary care. 3725 patients
coded for Lyme disease during 1998–2016 were identified within The Health Improvement Network (THIN).
Incidence rates and the demographics of cases identified were described. Poisson regression was used to analyse
socio-demographic characteristics of the cases.
Results: There was an increase in annual crude incidence rates, peaking in 2015 at 5.47 (95% CI 4.85–6.14) cases
per 100,000 population per year. Multivariable analysis showed there were significant differences in the ages of
those affected, incidence of a new diagnosis rose as deprivation levels improved, and that there was a higher
incidence of cases living in rural areas compared to urban areas. There was no significant difference between sexes
for the UK. Cases were significantly more likely to identify with being white compared to the national population.
Conclusions: An increasing incidence of patients newly coded with Lyme disease related Read codes was
identified using data from a UK national primary care database. By comparing these incidence figures with national
laboratory-confirmed surveillance data, a multiplication factor of 2.35 (95%CI 1.81–2.88) can be calculated in order
to estimate the annual number of cases seen in primary care. The significant socio-demographic variables
associated with a Lyme disease diagnosis likely reflect a complex interplay of socio-economic issues, which needs
to be further explored. Future work is needed to examine the treatment and management of patients within this
database.
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Background
Lyme disease, caused by some members of the spiro-
chaetal genospecies complex Borrelia burgdorferi sensu
lato, has been the topic of much debate and created
many headlines in the United Kingdom (UK) [1–3]. It is
transmitted by the bite of an infected Ixodes spp. of tick,
and is the most common zoonotic disease transmitted
by ticks in the Northern Hemisphere [4]. It has a variety
of clinical presentations, most usually including ery-
thema migrans, flu-like symptoms, and joint and muscle
pain, or more uncommonly neurological and cardiac
presentations [4–7]. Current recommendations are to
treat patients presenting with an erythema migrans rash
with antibiotics. Laboratory diagnostic tests are recom-
mended when erythema migrans is absent and if there is
clinical suspicion and a strong supportive history of
Lyme disease [7]. However, as the (National Institute for
Health and Care Excellence) NICE guidelines state,
‘there is a lack of robust epidemiological data on Lyme
disease in the UK’ [7]. This lack of knowledge includes
incidence data in different health care settings, basic pa-
tient demographic information, and an understanding of
current case management strategies by health care
professionals.
As notification of clinical cases is not required, na-
tional incidence figures in the UK are based on reports
of laboratory confirmed cases from the reference labora-
tories of Public Health England and Health Protection
Scotland [7, 8]. In 2016, the national incidence was 1.95
cases per 100,000 population in England and Wales, and
3.15 cases per 100,000 in Scotland. Over the last decade,
cases in England appear to be rising, whilst the incidence
in Scotland is reported to be stable [7–10]. A 2016 re-
view compared reported incidence across Western Eur-
ope and calculated a population-weighted average
incidence rate of 22.05 cases per 100,000 person-years
[11]. In the United States of America, a study of the inci-
dence of clinician-diagnosed Lyme disease calculated an
annual incidence of 106.6 cases per 100,000 persons
[12]. These differences in incidence are likely due to a
combination of differing surveillance methods and dif-
ferences in true incidence. Without a comprehensive
surveillance system and an internationally standardised
case definition, comparisons between nations proves
challenging.
Within a health care system, primary care manages
the greatest number of Lyme disease patients [4, 7, 12–
16]. Without understanding the potential burden for
general practitioners (GPs) and the demographics of
these patients, it is difficult to shape policy, deliver tar-
geted education to the general public and clinicians, per-
form financial assessments, or understand case
management strategies. The incidence of Lyme disease
identified within primary care in the UK is poorly
understood. There are two methods of recording pri-
mary care data; Read codes representing presenting
symptoms or diseases, and free-text narrative. Read
codes are a coded thesaurus of clinical terms that are
used in primary care electronic health records in the UK
and New Zealand [17]. A narrative analysis of health rec-
ord free text, on a national scale, would prove ethically
challenging due to difficulties in data anonymisation. On
the contrary, primary care databases coded via Read
codes are pseudo-anonymised and capture a large sam-
ple of the UK population. The aim of this study was to
describe the incidence of a new diagnosis, and demo-
graphics of Lyme disease as recorded in primary care be-




Population-based primary care data from The Health
Improvement Network (THIN) were used to identify pa-
tients with Lyme disease, suspected Lyme disease or
Lyme disease related conditions. The design of this study
was approved by the THIN Scientific Review Committee
(16THIN103).
THIN collects anonymised patient data from general
practices that use the VISION practice management
software [18]. In 2016, this software was used by 9 % of
all GP practices in England (this information is unavail-
able for the other UK nations; Northern Ireland,
Scotland and Wales). These practices opt-in for their
data to be made available in the THIN database. THIN
represents 11.1 million patients with around 4.0 million
annually active patients, collected from over 700 general
practices in the UK. An active patient is defined as one
being registered to a general practice currently supplying
data to THIN, who is not dead and has not left the prac-
tice since the last data collection point. THIN has repre-
sentative coverage of 6.1% of the UK population, and is
representative in terms of demographics, major condi-
tion prevalence and adjusted death rates [19]. All pa-
tients and general practices are pseudo-anonymised and
demographic information is available at patient level for:
age, sex, ethnicity, and nation of residence. There was
no available information about the geographic distribu-
tion of THIN reporting practices. However, the distribu-
tion of practice management software in English
primary care in 2016 was known [20]. All these systems
have high regional variability. VISION was the most geo-
graphically restricted, with coverage significantly lacking
in the North and East of England. It is unknown which
of the VISION practices are part of THIN, and what the
geographic coverage is in other nations. We cannot con-
clude how geographically representative the THIN data-
base is for the UK.
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The representativeness of ethnicity data within THIN
has been questioned, as the level of missingness at case-
level is high. Between 2000 and 2013, 60% of THIN pa-
tient records had missing ethnicity information [21].
Ethnicity data are based upon patient-provided informa-
tion categorised into the following 2011 census groups;
‘White’, ‘Mixed’, ‘Asian’, ‘Black’, and ‘Other’ [22, 23].
The remaining sociodemographic variables under as-
sessment were Townsend scores (an indicator of mater-
ial deprivation) [24], and rural urban classification.
Within THIN these data are not related directly to the
case but are based upon the case’s resident postcode,
and then linked to 2001 census data [25]. These data are
therefore not a direct measure of the case’s sociodemo-
graphics, but rather a proxy, and reflect the area that
cases reside in. Townsend scores were converted, by
THIN, from exact scores to quintiles of equal size. The
quintile of 1 includes patients living in the lowest 20% of
Townsend scores (i.e. the least deprived areas), whereas
the quintile of 5 includes the highest 20% and the most
deprived areas.
Participants and statistical analysis of the data
In primary care the presenting symptoms of a patient
are coded with Read codes. Currently we do not know
which set of symptoms clinicians use to code the patient
with ‘Lyme disease’. Our case definition was therefore
restricted to Read codes specific to Lyme disease and
suspect Lyme disease (Table 1).
The ‘Suspected Lyme disease’ and ‘Suspected erythema
migrans’ codes were only introduced as Read codes in
2014 [26]. Conditions with multiple aetiology, such as
Bell’s palsy, were not included. This strict definition was
chosen to minimise the number of false positives identi-
fied. Choosing strict case definitions will likely under-
estimate the number of cases and sensitivity may be lost,
as cases of mixed non-specific clinical signs could be
missed. These codes were used to identify patients
accessing primary care between 1st January 1998 and
31st December 2016. No other exclusions were placed
on the patients. The index episode was taken as the first
occurrence of any one of the Read codes identified in a
patient’s record. All calculations and demographic infor-
mation were derived from this date. There is scant infor-
mation on how to define a reinfection or relapse of
Lyme disease, with no standard time period to differenti-
ate between the two [27]. It was therefore decided that
any subsequent Lyme disease Read codes associated with
an identified case were not analysed. Identified cases
were excluded from denominator calculations. Denomi-
nators were calculated as the total annual number of
unique active patients in the THIN database. Crude an-
nual incidence of new diagnosis rates were calculated for
the whole dataset and were stratified by UK nation,
month of diagnosis, and Read code. Confidence intervals
of the incidence were calculated using Byar’s method.
Using the Office for National Statistics (ONS) mid-year
population estimates [25] and our calculated crude inci-
dence figures, national case number estimates were
calculated.
Using the cases identified within THIN and the THIN
denominator population, we assessed the following vari-
ables univariably with Poisson regression; year as a linear
term, sex, age, nation, Townsend quintile, and rural-
urban status. Significant variables were taken forward for
multivariable analysis.
Due to the poor recording of ethnicity within THIN,
the complete electronic health record of each identified
case was read to confirm ethnicity status, rather than
constructing a Read code search. It was not feasible to
read and confirm the denominator population and
therefore incidence could not be calculated. Instead, pro-
portions of ethnicity classification for cases were calcu-
lated and compared to the ONS national population
ethnicity data, using a Chi-squared test.
A ratio between the incidence of new diagnosed cases in
primary care and the incidence of laboratory-confirmed
cases was created. National laboratory data for the UK is
available between 2007 and 2016 and released in the UK
government’s annual Zoonoses report [7]. An annual ratio
was calculated by dividing the crude annual incidence of
new diagnosis for the THIN dataset by the annual inci-
dence published in the Zoonoses report. The mean annual
ratio, with associated confidence intervals, was calculated.
All statistical analyses were carried out using R language
(version 3.2.0) (R Core Team 2015), and results were
deemed significant where p < 0.05.
Results
In total 3725 unique patients were identified with a Read
code for Lyme, suspected Lyme disease, or related
Table 1 Read codes identifying Lyme disease patients in The





Lyme disease A871000 2386
Erythema migrans AA41.00 992
Suspected Lyme disease 1JN1.00 233
Suspected erythema migrans 1JN2.00 50
Acrodermatitis atrophicans chronica M21y000 30
Lyme arthritis N010A00 21
Lyme neuroborreliosis A871100 8
Borrelial lymphocytoma A871300 5
Lyme carditis A871200 0
Total 3725
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conditions Read code between 1st January 1998 and 31st
December 2016 (Table 1). The most frequently used
Read codes (‘Lyme disease’ and ‘Erythema migrans’) rep-
resented 89.1% (n = 3318) of all Read codes identified
with Lyme disease. The suspected Lyme disease codes
only represented 7.6% (n = 283) of all codes.
There was an increase in the crude incidence of a new
diagnosis of Lyme disease in UK primary care between
1998, 1.77 (95% CI 1.35–2.26) cases per 100,000, and
2016, 4.89 (95% CI 4.26–5.59) cases per 100,000 (Fig. 1,
Table 2).
This rise was seen in all nations except Wales. Across
the UK, cases displayed a seasonal pattern, with the
highest incidence of a new diagnosis in the summer,
peaking in July and August (Fig. 2). This seasonality was
seen in England and Scotland with incidence peaking in
July and August respectively. In Northern Ireland and
Wales no obvious trends were seen.
The ‘Lyme disease code’ rose until a peak in 2009 be-
fore steadily declining (Fig. 3). ‘Erythema migrans’ had a
lower incidence and peaked in 2011 before declining.
Both ‘Suspected Lyme disease’ and ‘Suspected erythema
migrans’ showed a sharp increase in incidence in 2015.
In 2016 ‘Suspected Lyme disease’ was the most prevalent
Read code in use.
All variables examined were statistically significant in
the univariable Poisson analysis and were taken forward
for multivariable analysis (Table 3).
The age band 41–45 years was chosen as the reference
for age analysis as this group contained the mean age for
the dataset (mean = 42.9, 95% CI 42.3–43.6). Information
relating to Townsend score was available for 93.6% (n =
3487) of cases. Rural urban classifications were only
available for English and Welsh cases, as Scottish and
Northern Ireland authorities do not record this measure.
Therefore, two multivariable models were created.
Model 1 excluded the rural urban classification, whilst
model 2 excluded nation and maintained the rural urban
classification.
Univariable analysis showed a significant increase in
the incidence of a new diagnosis with each year. There
was a significantly higher incidence of new diagnosis in
Fig. 1 Crude incidence of UK Lyme disease cases in The Health Improvement Network (THIN), 1998–2016. Dotted lines represent 95% confidence
intervals. Smoothed lines of best fit were calculated using the LOESS method
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women compared to men. Most age bands had a statisti-
cally significantly lower incidence to the reference range.
Adults between 56 and 65 had a significantly higher inci-
dence. There was no significant difference in incidence
between the following age groups; 46–50, 51–55, 66–70
and 71–75. Scotland had a statistically significant higher
incidence compared to England, whilst Wales and
Northern Ireland had a significantly lower incidence.
Table 2 Incidence of a new diagnosis of Lyme disease in UK primary care and estimated number of cases
Year UK incidence UK cases England incidence England cases N.I. incidence N.I. cases
1998 1.77 (1.35–2.26) 1035 (789–1321) 1.56 (1.14–2.09) 762 (557–1020) 0 (0–1.62) 0 (0–27)
1999 1.73 (1.35–2.19) 1015 (792–1285) 1.52 (1.13–2.01) 745 (554–986) 0.58 (0.05–2.68) 10 (1–45)
2000 2.03 (1.65–2.48) 1195 (972–1460) 1.85 (1.43–2.36) 911 (704–1162) 0 (0–1.22) 0 (0–21)
2001 1.93 (1.58–2.35) 1141 (934–1389) 1.83 (1.43–2.32) 905 (707–1147) 0.48 (0.04–2.22) 8 (1–37)
2002 2.86 (2.43–3.35) 1698 (1443–1989) 2.34 (1.89–2.87) 1162 (939–1426) 0.89 (0.18–2.86) 15 (3–49)
2003 2.18 (1.82–2.60) 1300 (1085–1551) 2.08 (1.67–2.57) 1038 (834–1283) 0 (0–1.08) 0 (0–18)
2004 2.89 (2.48–3.36) 1733 (1487–2014) 2.72 (2.25–3.26) 1365 (1129–1636) 0.42 (0.04–1.94) 7 (1–33)
2005 3.23 (2.80–3.71) 1951 (1692–2241) 2.46 (2.02–2.97) 1245 (1022–1503) 0.78 (0.15–2.48) 13 (3–43)
2006 3.53 (3.08–4.02) 2147 (1873–2445) 2.96 (2.49–3.51) 1509 (1269–1789) 1.11 (0.31–2.97) 19 (5–52)
2007 3.92 (3.46–4.43) 2404 (2122–2716) 3.29 (2.79–3.86) 1690 (1434–1983) 1.74 (0.66–3.82) 31 (12–67)
2008 4.26 (3.78–4.79) 2634 (2337–2961) 3.60 (3.08–4.19) 1865 (1596–2171) 1.43 (0.48–3.40) 25 (9–60)
2009 4.50 (4.00–5.03) 2802 (2490–3132) 3.68 (3.15–4.27) 1921 (1644–2229) 1.05 (0.29–2.81) 19 (5–50)
2010 4.23 (3.75–4.76) 2655 (2353–2987) 3.36 (2.84–3.94) 1769 (1495–2074) 0.69 (0.14–2.22) 12 (3–40)
2011 4.17 (3.69–4.69) 2639 (2335–2968) 3.15 (2.66–3.71) 1673 (1413–1970) 1.02 (0.28–2.73) 19 (5–50)
2012 3.75 (3.29–4.24) 2389 (2096–2701) 3.18 (2.68–3.74) 1701 (1434–2001) 2.02 (0.84–4.16) 37 (15–76)
2013 4.46 (3.96–5.01) 2859 (2539–3212) 3.42 (2.89–4.02) 1842 (1557–2165) 1.33 (0.44–3.16) 24 (8–58)
2014 3.36 (2.91–3.85) 2170 (1880–2487) 2.66 (2.17–3.22) 1445 (1179–1749) 0.98 (0.27–2.63) 18 (5–48)
2015 5.47 (4.85–6.14) 3562 (3158–3998) 4.06 (3.38–4.84) 2224 (1852–2652) 2.30 (1.03–4.52) 43 (19–84)
2016 4.89 (4.26–5.59) 3210 (2797–3670) 3.25 (2.55–4.10) 1796 (1409–2266) 0.98 (0.27–2.60) 18 (5–48)
Year Scotland incidence Scotland cases Wales incidence Wales cases
1998 5.21 (2.92–8.66) 265 (148–440) 1.61 (0.53–3.82) 47 (15–111)
1999 4.68 (2.78–7.42) 237 (141–376) 1.07 (0.30–2.85) 31 (9–83)
2000 4.17 (2.83–5.93) 211 (143–300) 0.85 (0.23–2.26) 25 (7–66)
2001 3.09 (2.23–4.51) 156 (113–228) 1.33 (0.50–2.91) 39 (15–85)
2002 5.70 (4.24–7.51) 289 (215–381) 3.01 (1.65–5.10) 88 (48–149)
2003 4.17 (2.96–5.73) 211 (150–290) 0.61 (0.17–1.64) 18 (5–48)
2004 5.59 (4.20–7.31) 284 (214–372) 0.90 (0.34–1.97) 27 (10–58)
2005 8.62 (6.87–10.68) 440 (351–546) 1.40 (0.66–2.64) 42 (20–78)
2006 8.22 (6.54–10.22) 422 (336–525) 1.34 (0.63–2.53) 40 (19–76)
2007 9.03 (7.30–11.06) 467 (377–572) 1.42 (0.70–2.58) 43 (21–78)
2008 10.13 (8.31–12.23) 527 (432–636) 0.91 (0.38–1.87) 28 (11–57)
2009 11.00 (9.11–13.16) 576 (477–689) 1.47 (0.76–2.62) 45 (23–80)
2010 10.06 (8.27–12.13) 529 (435–638) 2.43 (1.47–3.80) 74 (45–116)
2011 11.37 (9.46–13.55) 603 (501–718) 1.13 (0.53–2.13) 35 (16–65)
2012 8.18 (6.59–10.03) 435 (350–533) 1.37 (0.71–2.44) 42 (22–75)
2013 11.02 (9.17–13.13) 587 (489–700) 2.01 (1.17–3.23) 62 (36–100)
2014 8.29 (6.72–10.13) 443 (359–542) 0.65 (0.24–1.41) 20 (7–44)
2015 12.71 (10.73–14.94) 683 (577–803) 1.79 (1.03–2.92) 55 (32–90)
2016 10.74 (8.94–12.80) 580 (483–692) 2.54 (1.60–3.85) 79 (50–120)
NI = Northern Ireland
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The incidence rate ratio was significantly higher in the
second quintile, the same in the third and then declined
as Townsend quintile increased. There was a statistically
significantly higher incidence in patients residing in rural
areas compared to urban areas.
Multivariable analysis showed the same patterns in sig-
nificance for year and nation (Table 3, model 1). There was
no longer a significant difference between sexes. The only
age band to change was 31–35, which was no longer signifi-
cant. Townsend quintiles showed a significant decrease in
incidence rate ratio as Townsend quintile increased, apart
from quintile 2 which was significantly higher than 1.
Model 2 excluded nation from analysis but included rural
urban classification, thus essentially representing a model
of just English and Welsh cases. Incidence of a new diagno-
sis significantly increased with each year. Women had a sig-
nificantly higher incidence than men. The age band
variable changed the most compared to univariable analysis.
All ages were no longer statistically different to the refer-
ence age except, < 1, 1–5, 81–85,> 85 which were signifi-
cantly lower, and 56–60 which was significantly higher.
The Townsend quintiles showed a clear trend with inci-
dence significantly declining as quintile increased. Incidence
of new diagnosis was significantly higher in rural areas
compared to urban areas.
There was a high degree of missing data for ethnicity,
with only 35.1% (n = 1306) of cases providing information.
Of these, 73.5% (n = 960), had an ethnicity description that
matched the ethnicity categories defined in the UK 2011
census [23]; the remaining 346 all identified with being
‘British/Mixed British’. There was a significant difference in
ethnic diversity (p < 0.01), with a higher percentage of the
Lyme disease coded THIN patients (96%) identifying with
being white compared to the national population (87%).
The mean annual ratio between THIN crude incidence
figures and national laboratory-confirmed incidence fig-
ures was 2.35 (95% CI 1.81–2.88). The ratio ranged from
1.91 in 2012 to 2.82 in 2015.
Discussion
This study describes the incidence of a new diagnosis,
and demographics of Lyme disease coded patients using
Fig. 2 Monthly incidence of Lyme disease in The Health Improvement Network (THIN), 1998–2016
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primary care data in the UK, fulfilling one of the key re-
search needs identified by the NICE guidelines [7].
There has been an increase in the annual incidence of
newly coded Lyme disease patients in UK primary care
between 1998 and 2016. Incidence varied between na-
tions, with Scotland experiencing the highest incidence
of disease. There was a higher incidence of Lyme disease
coded THIN patients living in rural areas and within
areas of lower deprivation.
A UK study estimating Lyme disease incidence in pri-
mary care showed a higher incidence, with 12.1 cases
per 100,000 in 2012 [28]. This was about three times our
estimate for 2012 (Table 2). Our study used a more spe-
cific case definition, in line with the NICE clinical guide-
lines [7], and is likely to provide a conservative estimate.
Therefore, it is not possible to directly compare our re-
sults with those of the above paper as different case defi-
nitions were used and no stratification of results were
provided. European studies using similar data from pri-
mary care sentinel practices have described a large range
in incidence [14, 29, 30], from 42 cases per 100,000 per
year in France [13], to 148 per 100,000 per year in
Norway [15]. The UK had a much lower incidence rate
across the study period; 4.23 (95% CI 4.09–4.34) cases
per 100,000 person-year. The UK had its peak crude
incidence of new diagnosis in 2015, 5.47 (95% CI 4.85–
6.14) per 100,000 population. The annual incidence sig-
nificantly varied between nations; Scotland peaked in
2015 with an incidence of 12.71 (95% CI 10.73–14.94),
England in 2015 with 4.06 (95% CI 3.38–4.84), Northern
Ireland in 2015 with 2.30 (95% CI 1.03–4.52), and Wales
in 2016 with 2.54 (95% CI 1.60–3.85). Even in Scotland,
the incidence of Lyme disease is lower than in most
areas of continental Europe. The reasons for this are
likely to be multiple and need to be further explored.
They may include; a lower prevalence of Ixodes spp of
ticks, a lower prevalence of Borrelia spp carriage by ticks
(4.2% in southern England [31], 0–8.2% in northern
England [32], and 10.2% in Scotland [33], compared to
13.6% across Europe [34]), and different levels of
Fig. 3 Crude incidence of Lyme disease Read codes in The Health Improvement Network (THIN), 1998–2016. Dotted lines represent 95%
confidence intervals. Smoothed lines of best fit were calculated using the LOESS method. Only the four most prevalent Lyme disease Read codes
are displayed
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exposure of the general populace to ticks, possibly due
to differences in occupational and/or recreational dispo-
sitions. One possible explanation is lower awareness
about Lyme disease in the general population and
primary care in the UK, compared to the rest of Europe.
This would result in fewer presentations to primary care,
the potential for mis-diagnosis and a resultant underre-
porting of cases.
Table 3 Univariable and multivariable Poisson regression analyse for Lyme disease incidence of a new diagnosis in the UK
Univariable Analysis Multivariable Analysis Model 1 Multivariable Analysis Model 2
Independent Variable IRR (95% CI) p-value IRR (95% CI) p-value IRR (95% CI) p-value
Year (linear) 1.05 (1.05–1.06) < 0.001 1.05 (1.04–1.06) < 0.001 1.04 (1.03–1.05) < 0.001
Sex
Male 1 1 1
Female 1.08 (1.01–1.15) 0.02 1.06 (0.99–1.13) 0.08 1.20 (1.10–1.30) < 0.001
Age (Years)
< 1 0.04 (0.002–0.18) 0.001 0.04 (0.003–0.20) 0.002 0.07 (0.004–0.31) 0.008
1–5 0.55 (0.42–0.69) < 0.001 0.52 (0.40–0.67) < 0.001 0.65 (0.48–0.88) 0.006
6–10 0.76 (0.63–0.91) < 0.001 0.72 (0.59–0.87) < 0.001 0.95 (0.75–1.20) 0.67
11–15 0.66 (0.55–0.80) < 0.001 0.67 (0.55–0.81) < 0.001 0.88 (0.70–1.11) 0.29
16–20 0.63 (0.52–0.75) < 0.001 0.64 (0.53–0.78) < 0.001 0.87 (0.69–1.10) 0.25
21–25 0.64 (0.54–0.77) < 0.001 0.68 (0.56–0.81) < 0.001 0.85 (0.68–1.07) 0.18
26–30 0.78 (0.66–0.92) 0.004 0.81 (0.68–0.96) 0.02 0.96 (0.77–1.20) 0.74
31–35 0.80 (0.68–0.94) 0.006 0.85 (0.72–1.01) 0.06 0.86 (0.68–1.07) 0.17
36–40 0.82 (0.70–0.96) 0.012 0.83 (0.70–0.98) 0.02 0.89 (0.72–1.11) 0.30
41–45 1 1 1 1
46–50 0.98 (0.85–1.14) 0.83 0.97 (0.83–1.13) 0.72 0.94 (0.77–1.17) 0.60
51–55 0.98 (0.84–1.14) 0.80 0.92 (0.79–1.08) 0.33 0.92 (0.74–1.14) 0.45
56–60 1.27 (1.09–1.47) 0.002 1.23 (1.06–1.44) 0.007 1.25 (1.02–1.53) 0.03
61–65 1.25 (1.07–1.45) 0.004 1.19 (1.02–1.39) 0.03 1.02 (0.82–1.26) 0.89
66–70 1.01 (0.86–1.20) 0.86 0.99 (0.83–1.17) 0.89 0.98 (0.77–1.23) 0.84
71–75 0.89 (0.73–1.07) 0.21 0.89 (0.73–1.07) 0.21 0.85 (0.66–1.10) 0.23
76–80 0.63 (0.50–0.79) < 0.001 0.66 (0.52–0.83) < 0.001 0.77 (0.57–1.02) 0.07
81–85 0.43 (0.32–0.57) < 0.001 0.46 (0.33–0.61) < 0.001 0.50 (0.34–0.73) < 0.001
> 85 0.13 (0.08–0.20) < 0.001 0.14 (0.09–0.23) < 0.001 0.17 (0.09–0.29) < 0.001
Nation
England 1 1 N/A
Northern Ireland 0.36 (0.27–0.47) < 0.001 0.36 (0.26–0.48) < 0.001 N/A
Scotland 3.01 (2.82–3.22) < 0.001 3.16 (2.95–4.76) < 0.001 N/A
Wales 0.52 (0.44–0.61) < 0.001 0.56 (0.47–0.66) < 0.001 N/A
Townsend
1 1 1 1
2 1.29 (1.18–1.41) < 0.001 1.12 (1.02–1.22) 0.01 0.88 (0.79–0.99) 0.03
3 0.94 (0.85–1.03) 0.21 0.84 (0.76–0.92) < 0.001 0.66 (0.59–0.75) < 0.001
4 0.64 (0.58–0.72) < 0.001 0.54 (0.49–0.61) < 0.001 0.55 (0.48–0.64) < 0.001
5 0.41 (0.35–0.48) < 0.001 0.32 (0.28–0.37) < 0.001 0.43 (0.35–0.52) < 0.001
Rural Urban
Urban 1 1
Rural 1.96 (1.78–2.15) < 0.001 N/A N/A 1.71 (1.56–1.89) < 0.001
IRR Incidence rate ratio, CI Confidence Interval
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These differences in incidence of new diagnosis be-
tween nations are notable and likely to be multifactorial.
Scottish GPs may be more confident in diagnosing a
case of Lyme disease, due to the higher prevalence of
Lyme disease compared to England and Wales [7], and
so manage more patients within primary care without
submitting samples for serological testing. English and
Welsh GPs could be more reluctant to diagnose and
treat Lyme disease cases and may refer cases to second-
ary care sooner than their Scottish equivalents. There
may be differences in patient access to primary care or
differences in health-seeking behaviour between the dif-
ferent nations, dependent on differing clinical presenta-
tions. Further analysis of the THIN database may
provide information about case referrals, and differences
in case presentation and management. However, the ex-
ploration of differences in GP recording or patient be-
haviour would best conducted through qualitative
research.
The incidence figures are notable higher than those re-
ported in current surveillance figures based on labora-
tory confirmed cases [10]. The laboratory confirmed
incidence of Lyme disease in England and Wales in 2016
was 1.95 cases per 100,000 (95%CI 1.84–2.06) [7–9],
whilst that identified in THIN was 3.06 (95%CI 2.47–
3.75). The laboratory confirmed incidence of Lyme dis-
ease in Scotland in 2016 was 3.15 cases per 100,000
(95%CI 2.70–3.65) [7–9], in THIN it was 10.74 (95%CI
8.94–12.80). The laboratory confirmed incidence of
Lyme disease in Northern Ireland in 2016 was 0.21 cases
per 100,000 (95%CI 0.07–0.52) [7–9], in THIN it was
0.98 (95%CI 0.27–2.60). The large non-overlapping dif-
ferences suggest that the incidence described in primary
care data, for each nation of the UK, was significantly
larger than that described by official laboratory con-
firmed cases. The exception was Northern Ireland,
which may be due to the sparsity of Northern Irish cases
in the THIN dataset.
The mean annual ratio between primary care and la-
boratory confirmed incidence Figs. (2.35 (95%CI 1.81–
2.88)) suggest that for every laboratory-confirmed case
there are about two cases potentially identified within
UK primary care practices. This was to be expected as
not all cases of Lyme disease (in particular those with
erythema migrans) require confirmatory diagnostic la-
boratory tests. This ratio could be used as a multiplica-
tion factor to estimate the number of annual cases seen
in primary care based on laboratory confirmed cases.
The rise in the annual incidence of a new diagnosis of
Lyme disease, and the differences in incidence with the
laboratory datasets, could be a result of a real increase in
disease, an increasing awareness of the disease in the
general public, a change in general practitioners’ behav-
iour resulting in the submission of fewer diagnostic
samples, or a combination of the above. Further work is
needed to understand how general practitioners diag-
nose and manage Lyme disease cases. Wales is the only
nation that does not have an obvious increase in cases,
which may be due to, at least in part, a low number of
cases (n = 165) and registered THIN practices in Wales.
The peak number of cases we observed in summer
months is consistent with other studies [7, 10, 35–37].
This peak occurs slightly earlier in England than in
Scotland. This is likely due to latitudinal, climatic and
ecological differences between the two nations impacting
on, the emergence and peak numbers of nymphal ticks
[38]. The low case numbers in Wales and Northern
Ireland (n = 50) likely explain the lack of an obvious sea-
sonal trend.
Analysis of Lyme disease patient demographics have
shown predominance in both sexes in a variety health
care settings in the UK [7, 9, 10, 36, 37, 39]. In compari-
son to other national primary care datasets, Switzerland
and France have no statistical difference between sexes,
but numerically more women [13, 29]. Finland and
Norway have significantly more women [14, 15]. The re-
sults from THIN indicate no difference in the incidence
between sexes at a national level. However, local differ-
ences may exist relating to differences in tick exposure
or presentation to health services [40]. This was exem-
plified by the second model, representing England and
Wales, that had a higher incidence in women.
There is building evidence that areas with higher Lyme
disease incidence are likely to be less deprived [10, 37,
41, 42]. The current analysis was able to show that
socio-economic and rural-urban status were significantly
and independently associated with Lyme disease inci-
dence. There is obviously a complex interplay between
ethnicity, socio-economic status and place of residence
of a case, probably related with either outdoor employ-
ment or leisure activities. The results add to previous hy-
potheses that use and access to the countryside is a
driver of Lyme disease risk.
In England 45% of all outdoor visits were to the coun-
tryside, 68% of these were within two miles from their
starting point (usually a home address), and that people
were less likely to visit if they were from a BAME (Black,
Asian, minority ethnic) background, or from a ‘DE’ so-
cial group (i.e. semi-skilled and unskilled occupations,
unemployed and lowest grade occupations) [43]. In
Scotland, 50% of outdoor visits were taken in the coun-
tryside, the average distance travelled from home being
4.8 miles, and that people were less likely to visit if they
lived in the 15% most deprived areas, and were of ‘DE’
social grade; no difference in regards to ethnicity was
identified [44]. All ethnic minority groups are more
likely to live in areas of higher deprivation compared to
the white population, and there is a lack of ethnic
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diversity in wealthy areas [45]. Taking this into consider-
ation, we believe that members of the general population
who live in areas of low deprivation, predominantly rural
locations [46, 47], are more likely to identify with a
white ethnicity, and due to their residential location have
greater and closer access to the countryside. This in-
creased potential access to the countryside enables in-
creased risk of a tick bite and therefore subsequent risk
of developing Lyme disease. The lack of representation
of non-white ethnicity patients may also be due to inad-
equate healthcare access, lack of Lyme disease aware-
ness, or simply that erythema migrans rashes are harder
to identify on non-white skin colour [48, 49]. The latter
assumption would not hold true with other clinical pres-
entation, and it is recommended that ethnicity should be
explored in relation to clinical presentation prevalence.
The ethnicity data has a high degree of missingness,
74%, more so than prior analyses, 60% [21]. Its represen-
tativeness must therefore be questioned; our data only
provides a general indicator of the true situation.
With this large scale work we provide UK specific
baseline data that is greatly need for further epidemio-
logical research on Lyme disease, and have fulfilled one
of the NICE guidelines identified research needs [7]. We
have highlighted new insights into the demographics of
Lyme disease patients in primary care. THIN has been
shown to be representative of the UK population and as
such the results are likely to be representative of the
Lyme disease cases seen in primary care. The majority of
research investigating conditions within a primary care
database also try to validate the Read codes investigated.
This is usually via the result of a diagnostic test or a
questionnaire of general practitioners [50, 51]. Valid-
ation of Read codes relating to Lyme disease therefore
prove a challenge, as if there is an uncomplicated clinical
presentation the clinician is recommended to prescribe
antibiotics without performing subsequent diagnostic
tests [7]. Therefore, matching a Read code case with a
positive test result may be a fruitless exercise. Instead,
validation through a GP questionnaire would be recom-
mended. In the majority of cases there will be no con-
firmatory diagnostics, so GPs would have to confirm a
case by remembering the exact consultation, as the in-
formation collected by THIN does not substantially dif-
fer from what is in the practices’ clinical records. Hence,
there would be scope for considerable error. Method-
ology for validating conditions with broad clinical pre-
sentations needs to be explored, but this was beyond the
scope of this study.
Limitations
One of the largest limitations of this study is the absence
of knowledge about GP coding practices and changes in
their coding behaviour. Further work is required to
better understand coding practices and how they may
vary. The Read codes used by clinicians were consistent
until 2010, with the majority being ‘Lyme disease’ and
‘Erythema migrans’, at which point the use of these
terms started to decline. A year after the introduction of
the ‘suspected’ case codes in 2014, the ‘suspected’ codes
were already more prevalent in use than ‘Lyme disease’
and ‘Erythema migrans’. The reasons for the changes in
GP coding behaviour, potentially indicated by changes in
code incidence, are unknown; the change may be due to
the increasingly politicised landscape of Lyme disease
and the debate around ‘chronic Lyme disease’ [2, 52].
We need to know what symptoms are identified to code
a patient with ‘Lyme disease’; this could be only an ery-
thema migrans rash or another presentation described
by NICE [7]. Qualitative research around general practi-
tioners’ recognition and coding behaviour regarding
Lyme disease would help answer these questions. Only
25.8% (n = 960) of the study population had information
that could be analysed around ethnicity. We assumed
that the trends seen in this subset of patients is repre-
sentative of the THIN population as a whole; further
work is needed to verify this. Finally, the geographical
resolution of THIN only allows us to carry out analysis
to the level of the constituent nations of the UK, so ana-
lysis of the spatial distribution of incidence with this
dataset is not possible. Previous research in the UK has
shown clear clustering of cases both from laboratory
confirmed cases [7, 9, 36], and hospital admissions [37,
39]. The largest number of identified cases will be in pri-
mary care, because not all cases require diagnostics or
hospital admissions. Therefore, without greater reso-
lution, we cannot see whether the observed hotspots of
disease in laboratory surveillance systems are reflected in
primary care activity.
The multivariable Poisson regression must be treated
with a degree of caution as some of the data falls into
ecological fallacy. Both Townsend quintile and rural-
urban status are based upon information regarding the
area in which the patient resides rather than about the
individual patient. In no UK health datasets are these
variables directly attributable to the patient rather than a
geographic area. As these are important variables to ex-
plore the authors felt justified in analysing the data using
this methodology. The strong and significant associa-
tions suggest that this approach was justified. However
ecological fallacy must be acknowledged until the time
that these variables can be explored at patient level on a
national scale.
The NICE guidelines highlighted the ‘lack of robust
epidemiological data’ on Lyme disease in the UK, and
called for research in this area [7]. This research pro-
vides a description of the demographics and incidence of
a representative UK primary care population. This work
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will help ensure the appropriate public health prioritisa-
tion of Lyme disease in the UK, however, many basic
epidemiological questions remain unanswered. These
mainly revolve around person-tick interaction and in-
clude; the Borrelia spp. seroprevalence of the UK popu-
lation, the total exposure of tick bites to the UK
population, and the risk of contracting Lyme disease
after a tick bite in the UK. These final two points could
be explored using the THIN dataset.
Conclusions
Our data provides the primary care practitioners with
basic sociodemographic information about the type of
patient who is more likely to present with Lyme disease.
This information can be used to raise awareness of in-
creasing Lyme disease presentations in primary case and
their seasonality in the UK. This information is critical
to their diagnostic clinical decision making and ensures
that their clinical suspicion of Lyme disease is increased
in suitable situations. This research, alongside the NICE
guidelines [7], will raise Lyme disease awareness
amongst primary care clinicians and thus ensure that
Lyme disease is aptly placed on their differential diagno-
sis list. Patients are therefore less likely to be misdiag-
nosed and will be managed more appropriately. This will
only enhance Lyme disease patient care.
A multiplication factor was identified which could be
utilised to estimate the number of Lyme disease cases
seen in primary care. Comparing Lyme disease presenta-
tions in primary care with incidence in laboratory sur-
veillance systems can highlight areas where differences
exist regarding awareness, reporting, and management
of Lyme disease. These differences would require further
investigation. Future research using Lyme disease coded
patients within THIN, will investigate concurrent symp-
toms, and treatment and referral choices as part of case
management plans. This study provides a platform to
describe patient management in the UK primary care
setting and enables ongoing epidemiological analysis of
Lyme disease.
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